• Clearmind Medicine signed a research agreement to run a 12-month preclinical study testing its MEAI (CMND-100) alongside tirzepatide in diet-induced obese mice.
• Results have not been presented yet; the work will evaluate whether MEAI can improve durability of weight-management effects when used with tirzepatide or as a follow-on maintenance therapy.
• The study targets a key commercial weakness of GLP-1-based obesity drugs, where patients often regain weight when treatment stops, which can limit long-term outcomes and persistence.
• MEAI is positioned as a complementary approach aimed at sustaining metabolic benefits rather than relying solely on reduced food intake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180842PRIMZONEFULLFEED9722101) on May 18, 2026, and is solely responsible for the information contained therein.